Cargando…

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin’s lymphomas with poor clinical outcomes. Pralatrexate showed efficacy and safety in recurrent or refractory PTCLs. The purpose or this study was to investigate the efficacy and safety of pralatrexate in relapsed or refractor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Jung Yong, Yoon, Dok Hyun, Yoon, Sang Eun, Kim, Seok Jin, Lee, Ho Sup, Eom, Hyeon-Seok, Lee, Hye Won, Shin, Dong-Yeop, Koh, Youngil, Yoon, Sung-Soo, Jo, Jae-Cheol, Kim, Jin Seok, Kim, Soo-Jeong, Cho, Su-Hee, Lee, Won-Sik, Won, Jong-Ho, Kim, Won Seog, Suh, Cheolwon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937326/ https://www.ncbi.nlm.nih.gov/pubmed/31889144 http://dx.doi.org/10.1038/s41598-019-56891-0

Ejemplares similares

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
por: Yi, Jun Ho, et al.
Publicado: (2023)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
por: Cho, Hyungwoo, et al.
Publicado: (2023)

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
por: Yhim, Ho-Young, et al.
Publicado: (2020)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis
por: Yoon, Sang Eun, et al.
Publicado: (2020)

Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
por: Yi, Jun Ho, et al.
Publicado: (2021)

Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
por: Shin, Junghoon, et al.
Publicado: (2019)

Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
por: Yi, Jun Ho, et al.
Publicado: (2021)

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
por: Jeong, Seong Hyun, et al.
Publicado: (2022)

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
por: Kim, Seok Jin, et al.
Publicado: (2023)

Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial
por: Seo, Jeongkuk, et al.
Publicado: (2017)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
por: Oh, Sung Yong, et al.
Publicado: (2019)

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
por: Kwon, Jihyun, et al.
Publicado: (2016)

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study
por: Yhim, Ho-Young, et al.
Publicado: (2010)

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry
por: Yi, Hyeon Gyu, et al.
Publicado: (2013)

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)
por: Yoon, Dok Hyun, et al.
Publicado: (2016)

The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023)

Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study
por: Lee, Seul, et al.
Publicado: (2015)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2019)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party
por: Suh, Cheolwon, et al.
Publicado: (2013)

Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study
por: Kim, Seok Jin, et al.
Publicado: (2016)

Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement
por: Kim, Seon Young, et al.
Publicado: (2013)

Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study
por: Lee, Seong Jun, et al.
Publicado: (2014)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

PB1859: DNMT3A MUTATION PATTERNS AND CLINICAL FEATURES IN KOREAN ACUTE MYELOID LEUKEMIA PATIENTS
por: Lee, Eunyoung, et al.
Publicado: (2023)

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma
por: Hong, Junshik, et al.
Publicado: (2017)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2023)

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
por: Rai, Shinya, et al.
Publicado: (2022)

Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies
por: Lee, Eunyoung, et al.
Publicado: (2021)

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)
por: Yoon, Dok Hyun, et al.
Publicado: (2017)

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
por: Huang, Huiqiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2kku0suboth20k3rphue39badi